<DOC>
	<DOCNO>NCT00095706</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness combine treatment trastuzumab ( Herceptin ) bevacizumab ( anti-VEGF antibody ) patient HER2-positive metastatic breast cancer .</brief_summary>
	<brief_title>Treatment HER2-Positive Metastatic Breast Cancer With Herceptin Bevacizumab ( Antibodies Against HER2 VEGF )</brief_title>
	<detailed_description>Based preclinical experiment conduct laboratory , hypothesize aggressive behavior HER2-overexpressing breast cancer due part increase angiogenesis result HER2-induced increase vascular endothelial growth factor ( VEGF ) expression . In vivo experiment suggest combine blockade HER2 receptor VEGF result superior anti-tumor efficacy compare either treatment alone . The current clinical trial , phase I portion complete , examine efficacy safety trastuzumab ( Herceptin ) bevacizumab ( anti-VEGF antibody ) treatment HER2-overexpressing metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Metastatic relapse locally advanced breast cancer HER2positive FISH No prior chemotherapy metastatic disease ECOG performance status 02 Normal leave ventricular ejection fraction Bidimensionally measurable disease Oxygen saturation &gt; 90 % room air Other invasive malignancy within 5 year More 3 different metastatic site &gt; 50 % liver involvement metastasis Newly diagnose untreated Stage IIIB breast cancer Prior chemotherapy metastatic disease Clinically significant cardiovascular disease History evidence CNS disease Major surgery within 28 day prior day 0 Current recent use parenteral anticoagulant WBC &lt; 3,000/uL Platelet count &lt; 75,000/uL Hemoglobin &lt; 9.0 g/dL Total Bilirubin &gt; 2.0 mg/dL AST ALT &gt; 5 time upper limit normal subject document liver metastasis ; &gt; 2.5 time upper limit normal subject without evidence liver metastasis Proteinuria ( &gt; 1g protein/24 hour baseline ) Prior therapy Herceptin rhuMAb VEGF ( bevacizumab )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>VEGF</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
</DOC>